The Viscogliosis’ Holistic Approach to Back Pain Comes Into Focus
With the acquisition from Stryker Spine, a $707 million commercial powerhouse at one end of the spectrum, and a small-molecule drug in Phase III clinical trials for degenerative disc disease at the other end, the Viscogliosis are making good on their vision of offering a continuum of integrated technologies for treating chronic back pain.
Read Article